Lenvatinib-d4
Cat.No:ILA1808 Solarbio
CAS:2264050-65-7
Purity:≥98%
Qty:
Size:
{{cart_num}}
My CartCAS:2264050-65-7
Purity:≥98%
Qty:
Size:
CAS | 2264050-65-7 |
Name | Lenvatinib-d4 |
Purity | ≥98% |
Target Point | VEGFR;FGFR;PDGFR;c-Kit;RET |
Passage | Angiogenesis; Protein Tyrosine Kinase/RTK |
Background | Lenvatinib-d4 is a deuterium substitute of Lenvatinib. Lenvatinib is an orally active, multi-target tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR1-3), fibroblast growth factor receptor (FGFR1-4), platelet-derived growth factor receptor (PDGFR), Stem cell factor receptor (KIT) and intertransfection rearrangement (RET). |
Unit | Bottle |
Specification | 1mg |
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no experimental images.
Sorry, there is no more information.
Sorry, there is no more information.